Catalent To Expand Biologics Business With Agreement To Acquire Cook Pharmica
The acquisition will strengthen Catalent’s position as a leader in the rapidly growing area of biologics development and analytical services, manufacturing and finished product supply.
Catalent to Acquire Cook Pharmica, Positioning Catalent Biologics as a Leading Partner from Development to Commercialization
Upon closing,Catalent Biologics will acquire Bloomington, Indiana-based Cook Pharmica. By bringing together complimentary capabilities, the combined organization will provide biotech developers a Single Partner from cell line development through commercial supply of biologics in liquid and lyophilized vials, prefilled syringes and cartridges.
“The complementary biologics development, biomanufacturing, and fill-finish capabilities of Catalent and Cook Pharmica will provide biopharmaceutical firms with a single, integrated partner supporting a wide range of clinical and commercial needs,” said John Chiminski, Chair and CEO of Catalent.
The completion of the transaction is subject to customary closing conditions, including approval from regulatory authorities, and is expected to occur in the fourth quarter of this calendar year.
Catalent Biologics currently offers a global site network, including a state-of-the-art biologics development and biomanufacturing facility in Madison, Wisconsin; fill/finish services in Brussels, Belgium and Limoges, France; SMARTag® conjugation technology in Emeryville, California; and a network of biologics analytical locations.
Cook Pharmica’s Bloomington facility has extensive bio-manufacturing capacity and deep expertise in sterile formulation and fill/finish across liquid and lyophilized vials, pre-filled syringes, and cartridges. It will perfectly augment Catalent’s expertise in cell line engineering, bioconjugate development, analytical services, bio-manufacturing, prefilled syringe, and blow/fill/seal technologies upon successful closing.
In combination with Cook Pharmica, Catalent Biologics will be positioned to offer a comprehensive portfolio of integrated solutions to help biotech developers deliver better treatments to patients, faster.
- Cell Line Engineering – GPEx® Technology
- ADC & Bioconjugates –SMARTag® Technology
- Biomanufacturing – Clinical & Commercial
- Biologics Analytical Services –Integrated and Stand-Alone
- Fill/Finish - Cook Pharmica’s drug product business will bring 3 lines in Indiana that can produce up to 100M units annually, complementing Catalent’s existing 175M unit capacity across its pre-filled syringe and auto-injector lines in Brussels, Belgium.
- Clinical Supply Services & Solutions for Biologics
Contact Us about how we can help solve your most complex Biologic challenge.